Major depressive disorder (MDD) is a mood disorder that affects behavior and impairs cognition. A gene potentially important to this disorder is the brain derived neurotrophic factor (BDNF) as it is involved in processes controlling neuroplasticity.
| INTRODUCTION
Major depressive disorder (MDD) is a complex psychiatric disorder that not only negatively affects mood and behavior, but also impairs cognition. There is high lifetime prevalence for MDD in industrialized countries. For example, MDD is estimated to have a lifetime prevalence of ∼16.2% and ∼12% in the United States and Canada, respectively, (Kessler et al., 2003; Patten et al., 2006) . This disorder can severely affect social functioning of affected individuals, diminishing their quality of life, and increasing their risk of fatality through suicide (Bijl & Ravelli, 2000; Fredman, Weissman, Leaf, & Bruce, 1988; Kessler et al., 2006) . Despite limited understanding of its etiology, recent studies have highlighted biological underpinnings of MDD. For instance, magnetic resonance imaging studies of MDD patients have poorly in tasks regulated by these brain regions, such as spatial memory (Gould et al., 2007) , executive functioning (Lampe, Sitskoorn, & Heeren, 2004) and emotional memory (Weniger, Lange, & Irle, 2006 ), compared to healthy controls. A gene whose expression plays an important role in regulating cognition and behavior is the brain derived neurotrophic factor (BDNF). Altered expression of this gene has previously been linked with MDD (Molendijk et al., 2014) . In this review, we will discuss how genetic and epigenetic factors can alter BDNF function and expression and thus contribute to MDD. To initiate this discussion, we will first provide an overview of the biology of BDNF.
| BIOLOGY OF BDNF
The BDNF gene codes for a neurotrophin that is highly expressed in the central nervous system and regulates many different cellular processes that regulate behavior (Aid, Kazantseva, Piirsoo, Palm, & Timmusk, 2007; Pruunsild, Kazantseva, Aid, Palm, & Timmusk, 2007) . In the brain, Bdnf is expressed by glutamatergic neurons (Andreska, Aufmkolk, Sauer, & Blum, 2014; Zafra, Lindholm, Castren, Hartikka, & Thoenen, 1992) and glial cells such as astrocytes (Aliaga, Mendoza, & Tapia-Arancibia, 2009 ) and microglia (Parkhurst et al., 2013) . It is, however, not expressed by inhibitory neurons (Gorba & Wahle, 1999; Rocamora, Welker, Pascual, & Soriano, 1996) . BDNF is initially synthesized as a pre-pro-peptide and cleaved into pro-BDNF (∼32 kDa) when its signal peptide is removed upon translocation into the endoplasmic reticulum (Lessmann, Gottmann, & Malcangio, 2003) . It is then converted from pro-BDNF to mature BDNF (∼14.5 kDa) either intracellularly by endopeptidases such as furin at the trans-golgi network (Mowla et al., 2001) or extracellularly by plasmin upon neuronal activation (Pang, Nagappan, Guo, & Lu, 2016) ( Figures 1a and 1b) . Other extracellular enzymes, such as matrix metalloproteases like MMP7, can also readily convert pro-BDNF to mature BDNF (Lee, Kermani, Teng, & Hempstead, 2001 ).
The intracellular conversion of pro-BDNF to mature BDNF is controversial, as some studies have shown that pro-BDNF is rapidly converted to mature BDNF in primary hippocampal neurons and secreted into culture media (Matsumoto et al., 2008) , while other studies have observed pro-BDNF being secreted into the culture media of primary hippocampal neurons (Yang et al., 2009 ). However, more recent studies have observed that the efficiency of conversion from pro-BDNF to mature BDNF varies along developmental time points.
For instance, a study performed on mouse hippocampal lysates showed that both pro-and mature BDNF were low in expression at postnatal day 0 (Yang et al., 2014) . The expression of pro-BDNF peaked at postnatal day 15 and declined at later stages. In contrast, mature BDNF expression peaked at postnatal day 21 and predominated in adulthood (Yang et al., 2014) . Other studies have also revealed that pro-BDNF and mature BDNF are differentially enriched in different areas of the neuron. Pro-BDNF is enriched at the dendrites while mature BDNF is enriched at the cell body (Orefice et al., 2013) .
Once secreted into the extracellular matrix, mature BDNF and pro-BDNF subsequently interact with their cognate receptors tropomyosin related kinase receptor B (TrkB) and p75 neurotrophin receptor (p75NTR), respectively, to mediate their effects (Thomas & Davies, 
| TRANSCRIPTION REGULATION OF BDNF
The BDNF gene has a complex gene structure with 11 different exons in humans, nine different exons in rodents, and nine alternative promoters for both groups Pruunsild et al., 2007) (Figure 2 ). Despite this complexity, it is surprising that only the last exon, exon IX in both human and rodents, which codes for the BDNF pre-pro-peptide, is translated. All other exons are untranslated regions with a start codon present in exons I, VII, VIII, and IX in the human BDNF gene. Exons immediately downstream of all BDNF promoters are spliced to exon IX. As such, exon IX is present in all BDNF mRNA isoforms. It is likely that the role of the nine alternative promoters is to finely regulate the complex spatiotemporal expression of the BDNF gene. For example, BDNF isoforms containing exon IV and exon IX are highly expressed in human heart tissue, but not other isoforms (Pruunsild et al., 2007) . In human brain tissues, all exons are expressed, but to different degrees in different brain structures (Pruunsild et al., 2007) . Similarly, different Bdnf exons are also differentially expressed through different stages of embryonic development as observed in rodent embryos . The different promoters also allow Bdnf to respond to a | 145 greater variety of stimuli. For instance, corticosterone treatment in rats reduced total BDNF protein levels by reducing Bdnf exon II and exon IV transcription (Dwivedi, Rizavi, & Pandey, 2006) . When treated with the antidepressant desipramine, however, BDNF protein was increased in the hippocampus due to an increase in exon I and exon III transcription (Dwivedi et al., 2006) . In comparison, fluoxetine treatment increased Bdnf exon II transcription (Dwivedi et al., 2006 (Paoletti, Bellone, & Zhou, 2013; Simms & Zamponi, 2014) . Relevant to this review are studies that have identified transcriptional regulatory elements involved in mediating BP1 and BP4 response to L-VGCC and NMDA receptor activation ( Figure 3 ). For example, a previous study identified a cAMP-responsive element (CRE) present in rat BP1 that is between −87 and −80 bp from the transcriptional start site (Tabuchi, Sakaya, Kisukeda, Fushiki, & Tsuda, 2002) . This region was observed to be involved in rat BP1 response to neuron depolarization which activates L-VGCC (Tao, Finkbeiner, Arnold, Shaywitz, & Greenberg, 1998) . Deletion of CRE significantly impaired rat BP1 upregulation by neuron depolarization (Tabuchi et al., 2002) . Similarly, overexpression of dominant negative cAMP-response element binding protein (CREB), which is a transcription factor that binds to CRE, reduced rat BP1 response to neuron depolarization (Tabuchi et al., 2002) .
Human BP1 is similar to rat BP1 in that an orthologous CRE-like element is also present which is positioned between −72 and −65 bp from the transcriptional start site (Pruunsild, Sepp, Orav, Koppel, & Timmusk, 2011) . However, mutation of this site did not affect human BP1 response to neuron depolarization (Pruunsild et al., 2011) . In contrast, a separate region in human BP1 located between −242 and −166 bp upstream of the transcriptional start site, which contains an activator protein 1 (AP1)-like element (−183 to −177 bp) and
an asymmetric E-box-like element (−178 to −173 bp), is involved in regulating human BP1 induction to neuron depolarization (Pruunsild et al., 2011) . Deletion of this region abolished human BP1 activity from being upregulated by neuron depolarization (Pruunsild et al., 2011) . Although mutation of the AP1-like element did not affect human BP1 response to neuron depolarization, mutation of the asymmetric E-box-like element reduced human BP1 induction from 24-to 5-fold increase, suggesting that the asymmetric E-box-like element is involved in human BP1 response to neuron depolarization (Pruunsild et al., 2011) . Consistent with this observation, overexpression of transcription factors NPAS4 and ARNT2, which bind to the asymmetric E-box-like element as FIGURE 2 Diagrammatic representation of rodent and human BDNF gene structure. Unlike the mouse and rat BDNF gene, the human BDNF gene has two additional exons; Vh and VIIIh. Description of the different human BDNF mRNA isoforms is as shown in the lower panel.
Transcription by alternative promoters is a major source of BDNF mRNA isoforms although alternative splicing does also contribute to its variations. Small arrows at the 5′ of exons indicate transcriptional start site by alternative promoters. Start codons are present in some exons apart from exon IX however only exon IX encodes for the full BDNF protein. Pictures have been adapted from (Pruunsild et al., 2007) .
NPAS4-ARNT2 dimers, enhanced human BP1 induction to neuron depolarization (Pruunsild et al., 2011) . This region is presently identified as the basic helix-loop-helix-PAS transcription factor response element (PasRE). These studies therefore show that although rodent and human BP1 are responsive to neuron depolarization, there are species-specific differences in regulatory elements involved in mediating this process.
Another highly characterized BDNF promoter is BP4. A number of distinct regulatory elements in rat BP4 have been identified that are involved in upregulating rat BP4 activity in response to neuron depolarization. By cloning rat BP4 to a reporter gene followed by deleting sections of the promoter, a previous study identified a calcium response element (CaRE3) present between −38 and −31 bp upstream from the transcriptional start site (Shieh, Hu, Bobb, Timmusk, & Ghosh, 1998) . Electrophoretic mobility shift assay further showed that CREB binds to this region and overexpression of dominant negative CREB impaired upregulation of rat BP4 activity by neuronal depolarization (Shieh et al., 1998) . Apart from CaRE3, a second calcium response element, CaRE1, is also involved in rat BP4 response to depolarization.
From a series of systematic deletions and mutagenesis experiments, CaRE1 was identified between −72 and −63 bp upstream from the transcriptional start site of rat BP4 (Tao, West, Chen, Corfas, & Greenberg, 2002) . Yeast-one hybrid and electrophoretic mobility shift assays further identified CaRE1-dependent transcription factor (CaRF)
as the transcription factor that binds to this region (Tao et al., 2002) .
Using HEK-293T cells, which does not express endogenous CaRF, cotransfection of reporter-gene plasmid regulated by rat BP4 together with expression plasmid that expresses either full-length CaRF or truncated CaRF, showed that truncated CaRF impaired rat BP4 from being upregulated by neuron depolarization (Tao et al., 2002) . In addition to CaRE3, a third calcium response element, CaRE2, was identified between −49 to −44 bp from the transcriptional start site and is involved in mediating rat BP4 response to neuron depolarization.
Mutation of this region reduced rat BP4 response to neuronal depolarization due to the disruption of upstream stimulating factor (USF) 1 and USF2 binding sites (Chen et al., 2003) . Electrophoretic mobility shift assay showed USF1 and USF2 are transcription factors that interact with CaRE2 (Chen et al., 2003) . In addition, reporter gene assay showed that dominant negative USF1 and USF2 inhibited rat BP4 from being upregulated by neuron depolarization (Chen et al., 2003) . These studies, therefore, highlight three calcium response elements involved in upregulating rat BP4 response to neuron depolarization.
Apart from the CaREs, three other regulatory elements have been identified to be involved in regulating rat BP4 response to NMDA receptor activation. One of which is a NF-κβ binding site positioned −8 to +1 bp upstream from rat BP4 transcriptional start site.
Electrophoretic mobility shift assay showed that NF-κβ binds to this region (Lipsky et al., 2001 ) and deletion of this region impaired NMDA mediated induction of rat BP4 activity (Jiang et al., 2008) . Similarly,
FIGURE 3
Transcription regulatory elements involved in regulating BDNF/Bdnf promoters I and IV activity. (a) Promoter I and (b) Promoter IV. Positions of regulatory elements are derived from sequences from the studies described in the main text and aligned to hg38 or rn6 of the human and rat reference genomes, respectively. Transcription factors involved in regulating promoter response to neuronal activation are shown.
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pre-treating cells with double stranded DNA containing this NF-κβ binding site reduced rat BP4 response to NMDA (Jiang et al., 2008; Lipsky et al., 2001) . Another positive regulatory element identified in BP4 is the NFAT binding site which is positioned between +151 to +156 bp downstream from the transcriptional start site (Vashishta et al., 2009) . Mutation of the NFAT binding site in rat BP4
abolished NMDA mediated increase in reporter gene expression (Vashishta et al., 2009 ). In addition, shRNA knockdown of the NFAT isoform, NFATc4, reduced NMDA mediated increase in Bdnf mRNA (Vashishta et al., 2009 ). Furthermore, co-transfection of a reporter gene plasmid under the control of rat BP4 and an expression plasmid for NFATc4 increased rat BP4 response to NMDA (Vashishta et al., 2009) .
In contrast to these positive regulators, rat BP4 also contains a negative regulatory element: a class B E-box positioned at −13 to −8 bp from the transcriptional start site. This is a binding site for a basic helix-loop-helix protein, BHLHB2, that suppresses rat BP4 activity prior to cell stimulation (Jiang et al., 2008) . NMDA treatment, however, removed BHLHB2 binding to the E-box which increased rat BP4 activity (Jiang et al., 2008) . Thus, much has been learned about the regulatory elements in rat BP4 that regulate its response to neuron activation.
Similar to rat BP4, these transcriptional regulatory elements are also present in human BP4. For example, through sequence conservation between the human and rat BP4, transcription regulatory elements similar to rat BP4 were also observed in human BP4. These include CaRE which is known as CaRE1 in rat BP4 (−72 to −63 bp), USF-binding element (UBE) which is also known as CaRE2 in rat BP4
(−49 to −44 bp), CRE (−38 to −31 bp) which is known as CaRE1 in rat BP4, BHLHB2-response element (RE) (−13 to −8 bp), NF-κβ-RE (−8 to +1 bp), and NFAT-RE (+141 to +146 bp) ( Figure 3 ) (Pruunsild et al., 2011) . Similar to rat BP4, mutagenesis of UBE, CRE, and NF-κβ-RE significantly impaired human BP4 upregulation by neuron depolarization (Pruunsild et al., 2011) . Unlike its ability to repress rat BP4 activity, mutation of BHLHB2-RE impaired human BP4 upregulation by neuron depolarization, suggesting that it functioned as a transcriptional enhancer (Pruunsild et al., 2011) . In contrast to these transcriptional regulatory elements, mutation to CaRE and NF-κβ-RE did not affect human BP4 response to neuron depolarization. Similar to human BP1, PasRE was observed in human BP4 between −89 to −84 bp from the transcriptional start site (Pruunsild et al., 2011) .
Mutation to PasRE significantly reduced human BP4 upregulation in activity by neuron depolarization (Pruunsild et al., 2011) . Electromobility shift assay also showed that CREB bound to CaRE3, USF 1 and USF 2 bound to UBE, and the NPAS4-ARNT2 dimer binds to PasRE (Pruunsild et al., 2011) . Together, these studies show that although similar regulatory elements exist between human and rat BP4, regulatory elements involved in upregulating BP4 activity in response to neuron depolarization can vary differently between the species.
Similar to human BP1 and BP4, a systematic deletion of human BDNF promoter IX (BP9) identified a PasRE that overlaps with a CRE-like sequence (Pruunsild et al., 2011) . These regions are present in the 5′UTR from +714 to +719 bp and +718 to +725 bp, respectively, from the transcriptional start site. Mutation of these regions impaired human BP IX from being induced by neuronal depolarization (Pruunsild et al., 2011) . Electrophoretic mobility shift assay further showed that transcriptional activators ARNT2, CREB1, and USF bind to these elements (Pruunsild et al., 2011) . In line with this observation, overexpression of CREB1 or ARNT2, and NPAS4 enhanced human BP9 induction to neuron activation (Pruunsild et al., 2011) . Apart from the mentioned BDNF promoters, little is known about regulatory elements involved in regulating other BDNF promoters in response to neuronal activation.
As BDNF promoters mediate differential BDNF isoform expression in various parts of the brain, changes to their activity could affect cellular and behavioral phenotypes. For example, disruption of BP4 in mice significantly reduced the number of parvalbumin GABAergic neurons in the prefrontal cortex and impaired GABAergic activity (Sakata et al., 2009) . These mice displayed depression-like behavior as they had increased immobility time for tail suspension test and forced swim test (Sakata et al., 2010) . Similarly, they displayed anhedonia-like behavior as they had reduced preference for sucrose water. They also displayed increased latency to escape in learned helplessness test (Sakata et al., 2010) .
To investigate the cellular and behavioral effects of other Bdnf promoters, a more recent study by Maynard et al. (2016) To explore the cellular changes that contribute to aggression mediated by the disruption of BP1 and BP2, the study further assessed the expression of genes in the prefrontal cortex which have been known to be involved in aggressive behavior. These include in 5-hydroxytryptamine (5-HT) signaling and GABAergic genes (Maynard et al., 2016 transcription PCR revealed that 3′UTR-L was sevenfold higher in expression at the dendrites compared to the soma .
Consistent with this result, fluorescence in situ hybridization of transfected mouse primary hippocampal cultures revealed that green florescence protein (GFP) attached to 3′UTR-S was present in the perisomatic region, but not the distal dendrites . In contrast, GFP attached to 3′UTR-L, although also present in the soma, could be targeted to the distal dendrites . Interestingly, its localization to the dendrites was mediated by neuronal activity as inhibition of action potentials reduced localization of a reporter gene with 3′UTR-L to the dendrites . This study, therefore,
showed that the length of the 3′UTR could determine the subcellular localization of Bdnf mRNA transcripts. This finding is consistent with an earlier in situ hybridization study that showed exons I and IV localized to the soma, while transcripts containing exons II and VI were localized to the dendrites in rat hippocampus (Chiaruttini, Sonego, Baj, Simonato, & Tongiorgi, 2008) .
In addition to the 3′UTR, the coding sequence also contains a constitutive signal that promotes localization of Bdnf transcripts to the dendrites ( Figure 4 ). In another study by Chiaruttini et al. (2009) (Chiaruttini et al., 2009 ). This study highlights that the coding region and the 5′UTR also play a role in determining the sublocalization of Bdnf transcripts in addition to its regulation by the 3′UTR.
Apart from subcellular localization, the 3′UTR is also known to mediate the localized translational behavior of Bdnf mRNA transcripts.
FIGURE 4
Components of Bdnf mRNA that regulate its sub-cellular localization. The coding sequence contains a translin binding site that enables translin to recruit transcripts to the dendrites. This binding site overlaps with the SNP rs6265. Translin-mediated recruitment to the dendrites can be repressed by sequences from the 5′UTR such as exon I and exon IV. This results in the transcripts being retained within the area of the soma. In contrast, exon II and exon VI do not repress translin-mediated recruitment permitting the transcripts to be localized to the dendrites. The 3′UTR also regulates the sub-cellular localization of transcripts. While the short 3′UTR localizes transcripts to the soma, the long 3′UTR permits transcripts to be recruited to the dendrites. Both translin and long 3′UTR are involved in activity-mediated recruitment of transcripts to the dendrites.
Indeed, when destabilized GFP with a myristoylation peptide cloned to 3′UTR-L was transfected into rat hippocampal cultured neurons, GFP was expressed at the distal dendrites . This was not due to the diffusion of GFP from the soma as the myristoylation peptide and short half-life of the destabilized GFP prevented diffusion of GFP from the soma to the dendrites. Furthermore, inhibition of action potentials by tetrodotoxin reduced GFP expression at the dendrites while inducing neuronal activation by tetraethylammonium increased its localized expression (Lau et al., 2010) . In contrast, GFP cloned with the 3′UTR-S was expressed in the soma and was not affected by tetrodotoxin or tetraethylammonium, showing that it is not involved in activity-mediated translation Lau et al., 2010) . In short, Bdnf mRNA transcripts containing 3′UTR-S are localized and translated at the soma to maintain basal levels of Bdnf. In comparison, 3′UTR-L transcripts can be actively recruited to the distal dendrites by neuron activation for activity-dependent local translation.
While they code for the same protein, the varying subcellular localizations of the BDNF isoforms determine the differential cellular effects of this gene. Bdnf exon IV is predominantly expressed in the perisomatic region of neurons as mentioned above. It regulates the development of parvalbumin GABAergic neurons which has its projections to the perisomatic region of excitatory neurons (Woo & Lu, 2006) . Reduced expression of Bdnf at the cell body in mice, resulting from disrupted BP4 activity, significantly reduced the number of parvalbumin GABAergic neurons in the prefrontal cortex (Sakata et al., 2009 ). This resulted in a significant reduction in the amplitude and frequency of spontaneous inhibitory postsynaptic currents and impaired suppression of spike-timing dependent potentiation (Sakata et al., 2009 ). These mice also displayed depression-like behavior (Sakata et al., 2010) . In a separate study, mice containing the loss of Bdnf 3′UTR-L isoforms, which is localized to the distal dendrites, showed significant increase in spine density at distal apical dendrites in the hippocampus due to impaired spine pruning, which is a Bdnf dependent event . Long term potentiation, which is a persistent increase in synaptic strength mediated by Bdnf, was also observed to be impaired .
| REGULATION OF BDNF TO SECRETORY PATHWAYS
In addition to mechanisms controlling BDNF subcellular localization and translation, another mechanism exists to regulate its trafficking to the secretory pathway. In a study by Chen et al. (2005) a binding site for a Vps10 domain protein, sortilin, was identified at the pro-domain of pro-Bdnf. This protein was observed to mediate targeting of BDNF into secretory granules for activity-mediated secretion. Truncation of sortilin or mutation of its binding site at the pro-domain of Bdnf impaired activity-mediated secretion of Bdnf under depolarizing conditions (Chen et al., 2005) . This mechanism plays an important role in enabling BDNF to mediate synaptic plasticity as activitydependent secretion is required for processes such as LTP (Santi et al., 2006) . Impairment of this mechanism has been shown to affect episodic memory (Egan et al., 2003 This change affects how BDNF is regulated and has an impact on cognition. For example, the G → A transition disrupts the translin binding site, which impairs dendritic targeting of BDNF mRNA (Chiaruttini et al., 2009 ). This results in the perisomatic localization of BDNF as observed in cultured neurons that are transfected with plasmids that express BDNF containing this variant (Egan et al., 2003) .
Furthermore, the methionine change also disrupts the sortilin binding site, impairing activity-mediated secretion of BDNF (Chen et al., 2005) .
As a result of altering BDNF subcellular localization and secretion, the "A" allele was observed to alter hippocampal activation, lower hippocampal synaptic activity, and impair episodic memory in humans (Egan et al., 2003) . These studies, therefore, underscore how a single SNP could disrupt BDNF post-transcriptional and secretory processing, resulting in cognitive deficits. Following the demonstration that this SNP is functionally relevant, many investigators have sought to explore its role in mood disorders.
Presently, research into the relationship between rs6265 and MDD is inconclusive (Table 2) . Many previous studies have associated the minor allele "A" with MDD as well as heightened suicide risk (Hong et al., 2003; Hwang et al., 2006; Licinio, Dong, & Wong, 2009; Ribeiro et al., 2007) . Other studies, however, showed weak or absent association with MDD (Hong et al., 2003; Li, Chang, & Xiao, 2016; Liu et al., 2009; Schumacher et al., 2005) . A meta-analysis by Gyekis et al. reported that out of 23 studies on rs6265, only three demonstrated significant association with MDD, and that of the three, the two strongest results presented associations in opposite directions (Gyekis et al., 2013) . This lack of association has also been replicated in a recent meta-analysis (Li, Chang, et al., 2016) . Despite the absence of clear association, limitations to current meta-analyses prevent definitive exclusion of rs6265 as a candidate SNP for MDD (Gyekis et al., 2013) . The subject populations between studies vary in gender distribution, ethnicity, and study method; some studies also used small subject pools, and may have defined or measured MDD by different scales ( Table 2) . As a result, inadequate control for these factors could have influenced the outcome of the current studies. Although a separate meta-analysis did identify an overall lack of association between rs6265 and MDD, gender stratification analysis showed significant effects in men where the minor allele "A" was carried more often by male cases than controls (Verhagen et al., 2010) . This gender stratification analysis was not performed by Gyekis et al. (2013) and Li, Chang, et al. (2016) due to limited data. Further studies are required to replicate this finding.
In addition to its possible relationship with MDD susceptibility, rs6265 may also interact with negative stressors to influence the severity of MDD. For instance, adverse childhood experience is a major environmental risk factor for MDD. Studies have observed that the "A" allele promotes adult depressive symptoms more strongly than the "G" allele in subjects that experienced childhood adversity (Aguilera et al., 2009; Frodl et al., 2014) . This genotype effect was further observed to moderate the hippocampal volume of MDD patients who experienced childhood adversity by magnetic resonance imaging studies. In line with previous studies showing that hippocampal volume is reduced in MDD patients (Lorenzetti et al., 2009 ), carriers of the "A" allele who experienced childhood adversity had smaller hippocampal volumes compared with those homozygous for the "G" allele (Carballedo et al., 2013; Frodl et al., 2014 ). This finding is not shared by some other studies (Nederhof, Bouma, Oldehinkel, & Ormel, 2010) . However, a recent meta-analysis using a combined sample of 10,521 individuals showed a trend toward significance for the interaction between the "A" allele and childhood adversity (Hosang, Shiles, Tansey, Mcguffin, & Uher, 2014) . This suggests a weak interaction may exist between rs6265 and childhood adversity. Apart from childhood adversity, rs6265 has also been shown to moderate the effect of stressful life events on MDD. The "A" allele was associated with increased prevalence of depression events with increasing number of stressful life events (Brown et al., 2014; Kim et al., 2007) . A meta-analysis that used 11 studies and a total of 7,594 individuals observed a significant interaction between the "A"
allele with stressful life events (Hosang et al., 2014) . Together, these studies suggest a strong interaction between the "A" allele and stressful life events, along with a weaker interaction of this allele with childhood adversity to moderate depression development. Interestingly, this BDNF genotype may not only interact with negative stressors, but may also interact with polymorphisms of other genes, such as those in the serotonin transporter gene, to moderate the effect of negative stressors on the development of mood disorders.
The serotonin transporter is encoded by the gene SLC6A4. It is a transmembrane protein involved in terminating the action of serotonin in the synapse by reuptake. Its promoter contains a region with variable number tandem repeats resulting in a short ("s") or a long ("l") allele. The "s" allele results in a truncated promoter that has reduced transcriptional efficiency compared to those with the "l" allele. This "s" allele was previously associated with the development of depression in subjects with a history of childhood abuse and recent stressful life events (Caspi et al., 2003) . Interestingly, rs6265 has been observed to interact with this serotonin transporter polymorphism to moderate depression development. For example, maltreated children with the "A"
allele for rs6265 and "s/s" genotype for the serotonin transporter promoter had the highest depression score (Kaufman et al., 2006) .
Although this finding was similarly observed in a separate replication study (Wichers et al., 2008) , subjects with the "A" allele for rs6265 and "s/l" for the serotonin transporter promoter had the highest depression score instead (Wichers et al., 2008) . Although these studies support an interaction between rs6265 and the serotonin transporter promoter polymorphism in moderating depression severity, these observations were not replicated in two other studies, suggesting that other moderating factors may be involved (Aguilera et al., 2009; Nederhof et al., 2010) . Taken together, although altered BDNF processing by the "A" allele affects memory, there is presently weak support for its contribution to MDD susceptibility. There is, however, some evidence to suggest its role in moderating the effect of negative stressors on depression development. Apart from rs6265, there are presently no other SNPs in the protein-coding region of BDNF that have been associated with mood disorders (Table 3) . Other SNPs are reported to be present in the non-coding regions at the BDNF locus.
| CONTRIBUTION OF rs12273363 TO MOOD DISORDERS
Although much is still unknown about the function of non-coding Independent sample = a sample group composed of subjects not shared with other groups within the study. *Meta-analysis. **Not reported in study.
α-thalassemia, where the risk allele of a SNP present between the α-globin genes and their upstream regulatory elements formed a novel regulatory site that reduced the expression of α-globin genes (De Gobbi et al., 2006) . Likewise, in a separate study, a SNP associated with colorectal cancer was found to be present in a region that promotes MYC oncogene expression (Tuupanen et al., 2009 ). The risk allele enhanced responsiveness to Wnt signaling, which is a major pathway in colonic neoplasia, and increased MYC expression (Takatsuno et al., 2013; Tuupanen et al., 2009) . Given the function of non-coding regions, SNPs present in the non-coding region at the BDNF locus could similarly alter BDNF gene expression contributing to mood disorders. This was indeed observed for rs12273363.
The SNP rs12273363 was previously observed to contribute to MDD. This SNP was observed to be involved in depression as the minor allele "C" was observed to interact with childhood adversity to moderate lifetime depression (Juhasz et al., 2011) . To explore the functionality of rs12273363, a study by Hing et al. (2012) showed that this SNP is present upstream of the BDNF gene in an intergenic region that represents ∼92 million years of divergent evolution. This region not only suppressed BP4 activity, but also functioned as a filtering element by selecting signaling cues for BP4 to respond (Hing et al., 2012) . For example, it allowed BP4 to be activated by neuron depolarization, but not by protein kinase A and protein kinase C pathways individually (Hing et al., 2012) . The "C" allele further suppressed BP4 response to neuron depolarization in primary hippocampal cultures (Hing et al., 2012) . This suggests that the "C"
allele could reduce BDNF expression in the hippocampus. Indeed, a previous post-mortem study using hippocampus tissue derived from MDD and BD patients, who were homozygous or heterozygous for the "C" allele of rs12273363, had significantly reduced hippocampal BDNF protein levels compared to those who were homozygous for the "T" allele (Dunham, Deakin, Miyajima, Payton, & Toro, 2009 ). This suggests that altered BDNF expression mediated by this SNP may contribute to the development of mood disorders.
Apart from rs12273363, the function of other SNPs within the non-coding region of BDNF has not been empirically explored. It is, however, conceivable that SNPs present in non-coding regions of the gene body such as introns could similarly alter transcription or affect splicing of the pre-RNA transcript. Such effects have been observed by SNPs in the intron of other genes (Lettice et al., 2003; Seo et al., 2013) .
In addition to SNPs, other factors such as negative stressors can also alter BDNF expression, which can have a negative impact on behavior. (Jiang et al., 2017; Ping, Qian, Song, & Zhaochun, 2014; Suri et al., 2013) . In other studies, rats exposed to chronic restraint stress showed increased apoptosis in the hippocampus (Kang, 2015; Wang et al., 2016) . Consequently, these animals display spatial memory deficits and depression-like behavior (Jiang et al., 2017; Ping et al., 2014; Suri et al., 2013) .
| CELLULAR EFFECTS OF STRESS-INDUCED CHANGES TO BDNF EXPRESSION IN THE BRAIN
In addition to neurogenesis and apoptosis, reduced Bdnf expression due to stress can also cause atrophy of dendrites of pyramidal neurons and impair LTP. As observed from studies using the chronic In other stress paradigms, stress has also been observed to compromise GABAergic neuronal development and activity. In a study where rats were exposed to chronic mild stress, Bdnf exon IV expression was reduced in the hippocampus (Molteni, Rossetti, Savino, Racagni, & Calabrese, 2016) . Its upregulation by neuron activation was also dampened (Molteni et al., 2016) . Consistent with the role of Bdnf exon IV in the development of parvalbumin-, and, to a lesser degree, calbindin-positive GABAergic neurons (Sakata et al., 2009 ), chronic mild stressed rats had a pronounced reduction in parvalbumin-positive neurons, but a smaller reduction in calbindin-positive neurons (Czéh et al., 2015) . Other studies have also observed GABAergic neuron activity impaired by chronic mild stress (Nieto-Gonzalez et al., 2015) . Together, these studies highlight that reduction of Bdnf levels by stress can negatively affect neuroplasticity processes and GABAergic neuron activity, contributing to cognitive deficits and depression-like behaviors in rodents. Elevating Bdnf levels should therefore provide therapeutic benefit.
In line with the therapeutic effect of Bdnf, an earlier study where exogenous Bdnf was infused into the dentate gyrus of the hippocampus of rats significantly improved their ability to overcome learned helplessness behavior and improved their performance in the forced swim test (Shirayama, Chen, Nakagawa, Russell, & Duman, 2002) . Subsequent studies showed that conditions that HING ET AL.
promoted Bdnf expression such as exercise and the use of pharmacological agents, including antidepressants and ketamine, improved neurogenesis (Jiang et al., 2017; Ping et al., 2014; Suri et al., 2013) , arborization (Jiang et al., 2015; Yang et al., 2015) , LTP (Azadbakht et al., 2016; Radecki et al., 2005) , and GABAergic activity (Nieto-Gonzalez et al., 2015) , and reduced apoptosis (Kang, 2015; Wang et al., 2016) , resulting in the amelioration of depression-like behavior induced by stress. In contrast, conditional knockout of Bdnf in the forebrain prevented antidepressants and other pharmacological agents like ketamine from rescuing stress induced depression-like behaviors (Autry et al., 2011; Monteggia et al., 2004) . These studies highlight the role of Bdnf in rescuing depression-like behavior. It should, however, be pointed out that while elevated Bdnf levels may be beneficial for alleviating depression-like behavior and cognitive deficits, some studies have also observed that Bdnf overexpression in the brain of male or female mice can also result in cognitive deficits and the display of anxiety-like traits despite no observable changes to pro-BDNF levels (Cunha et al., 2009; Govindarajan et al., 2006; Papaleo et al., 2011) . Taken together, these studies suggest that the tight regulation of BDNF expression is required for mental health as over-or under-expression of Bdnf could impair cognition and contribute to anxiety or depression-like behavior.
In contrast to the benefits of elevated Bdnf levels, elevation of pro-BDNF expression by stress can also promote its negative effects, as pro-BDNF opposes the role of mature BDNF in mediating neuroplasticity. In a study where pregnant female rats were exposed to chronic prenatal restraint stress, their 5-week-old offspring had elevated pro-BDNF expression in the CA1 of the hippocampus (Yeh, Huang, & Hsu, 2012) . This was due to the reduction of tissue plasminogen activator expression, which reduced extracellular conversion of pro-BDNF to mature BDNF (Yeh et al., 2012) . This resulted in the loss of synaptic efficacy favoring LTD and opposed the induction of LTP (Yeh et al., 2012) . Stress can also impair arborization through increase in pro-BDNF expression. In a recent study where rats were exposed to unpredictable chronic mild stress, these rats had significantly increased expression of pro-BDNF, its receptor p75NTR, and co-receptor sortilin in the hippocampus and neocortex (Bai et al., 2016) . Consistent with the cellular effects of pro-BDNF, there was a significant decrease in neuronal spine length at the hippocampus and neocortex (Bai et al., 2016) . These rats displayed depression-like behaviors in the form of increased immobility in the open field and forced swim tests (Bai et al., 2016) . In contrast, when these rats were treated with anti-pro-BDNF antibodies, neuronal spine length in the hippocampus, and neocortex increased and their depressive-like behavior was ameliorated (Bai et al., 2016) . These studies, therefore, highlight that negative stressors can mediate their effects through pro-BDNF expression.
Although animal models provide a controlled environment to explore the impact of stress on the brain, the extension of these findings to humans may be limited as the models may not accurately recapitulate the heterogeneity of negative stressors experienced by mood disorder patients. As a result, clinical and postmortem studies have also been performed to study the relationship between BDNF expression and mood disorders, and to determine the cellular impact resulting from changes to BDNF expression. I-BDNF could cross the blood-brain-barrier (Pan et al., 1998) . BDNF was also observed to efflux from the brain as Due to this relationship between the brain and blood, many studies have used BDNF from serum or plasma of peripheral blood to investigate how BDNF expression is altered in mood disorders. This is with the presumption that any detectable changes would be reflective of similar changes in the brain. There are, however, concerns over this presumption as other tissues could also contribute to BDNF levels in the blood, including platelets (Tang, Chu, Hui, Helmeste, & Law, 2008) , activated human T cells, B cells, monocytes (Kerschensteiner et al., 1999) , and vascular endothelial cells (Nakahashi et al., 2000) .
| ALTERED BDNF LEVELS IN MOOD DISORDER PATIENTS AND ITS CELLULAR EFFECTS
Nonetheless, a positive relationship in BDNF level has been observed between brain-blood/serum/plasma across different species such as rats and pigs (Karege, Schwald, & Cisse, 2002; Klein et al., 2011; Sartorius et al., 2009 ). Thus, BDNF from the peripheral blood may reflect BDNF levels in the brain, making blood measurement a useful tool to explore the relationship between BDNF level and mood disorders in patients.
To explore if BDNF levels vary with MDD, BDNF from plasma or serum of MDD patients have been compared with that of healthy controls. A recent large prospective study containing 2,044 participants showed that serum BDNF was significantly reduced in current MDD patients compared to healthy controls and remitted patients (Molendijk et al., 2011) . This finding was similarly observed in a metaanalysis that included 99 studies involving 2,436 MDD patients and 8,795 healthy controls. The study showed that patients with acute MDD episodes had lower BDNF level in serum and plasma relative to healthy controls (Fernandes, Berk, Turck, Steiner, & Goncalves, 2014) .
This finding has since been observed in another meta-analysis (Molendijk et al., 2014) . In contrast, antidepressant treatment, which alleviates MDD symptoms, elevated BDNF, resulting in no detectable difference between antidepressant-treated MDD patients and healthy controls (Fernandes et al., 2014; Molendijk et al., 2011 Molendijk et al., , 2014 .
Similarly, no difference in BDNF level was observed between remitted patients and healthy controls (Fernandes et al., 2014; Molendijk et al., 2011 Molendijk et al., , 2014 .
Interestingly, although previous studies have shown a negative correlation between BDNF level and MDD severity (Lee, Kim, Park, & Kim, 2007; Shimizu et al., 2003) , this negative relationship was not replicated in a prospective study (Molendijk et al., 2011) . Additionally, although this negative relationship was initially detected in a metaanalysis, the association was removed after correcting for publication bias (Molendijk et al., 2014) . These conflicting findings call into question whether a genuine negative relationship exists between BDNF level and MDD severity. However, a more recent study did observe this negative relationship in female patients who were drug naïve, but not in male patients (Kreinin et al., 2015) . Thus, gender may play a role in this relationship. Further investigation is needed to replicate this finding.
To study whether changes in BDNF expression in the blood might similarly vary in the brain of mood disorder patients, investigators have relied on postmortem brain tissues. Consistent with the reduction in peripheral BDNF levels, reduced BDNF expression is also observed in the prefrontal cortex of MDD suicide completers (Dwivedi et al., 2003) . However, other studies have not detected changes in BDNF expression in the hippocampus or anterior cingulate cortex of postmortem samples from MDD patients (Knable et al., 2004; Thompson Ray, Weickert, Wyatt, & Webster, 2011; Tripp et al., 2012) . Instead, expression of the BDNF cognate receptor, TrkB, has been observed to be reduced in these studies, which highlight the contribution of altered BDNF signaling in major depression (Thompson Ray et al., 2011; Tripp et al., 2012) . In line with the effects of reduced BDNF signaling, GABAergic neuron density and dendritic arborization is reduced in the brain of MDD. In one such study, MDD post-mortem hippocampal tissue showed increased packing density of neuron and glial cells due to reduced neuron dendritic spine branching and dendritic spine complexity (Stockmeier et al., 2004) . Postmortem prefrontal cortex tissues from MDD patients also showed reduction in the density of GABAergic calbindin positive neurons (Rajkowska, O'dwyer, Teleki, Stockmeier, & Miguel-Hidalgo, 2007) . As reduced BDNF signaling can reduce GABAergic neuron density and neuron dendritic arborization, these postmortem studies suggest that reduced However, it remains a plausible mechanism that requires further investigation. One way by which stress can mediate its effect is through epigenetics.
| NEGATIVE STRESS ALTERS BDNF EXPRESSION THROUGH DNA METHYLATION
Epigenetics is the mechanism that enables cells (Sandoval et al., 2011) . Changes to DNA methylation patterns at these CpG contexts can result in changes to gene expression.
For instance, methylated cytosine in the CpG context has been shown to inhibit transcription factors from interacting with their regulatory elements, which, in turn, reduces transcription (Iguchiariga & Schaffner, 1989; Watt & Molloy, 1988) . Consistent with these studies, genomewide DNA methylation studies between normal cells and cancer calls have shown a negative relationship between DNA methylation and gene expression (Irizarry et al., 2009b; Rechache et al., 2012) . These studies also showed that differentially methylated regions are disproportionately enriched outside of CpG islands, in CpG shores, CpG shelves, and
CpG open sea, highlighting that methylation patterns at these regions promote differentiation of cellular phenotypes (Hing et al., 2015; Lee et al., 2011; Sandoval et al., 2011) .
In addition to establishing cellular phenotypes, DNA methylation can also regulate BDNF expression in response to changes in HING ET AL.
environmental conditions. It regulates this change by recruiting transcription repressive complexes to regulatory regions, such as promoters, to repress transcription. Reduction in DNA methylation can result in the dissociation of these repressive complexes enabling increase in transcription. For example, under basal conditions, cultured rat neurons contained CpG sites which were methylated at BP4 (Martinowich et al., 2003) . This resulted in localization of a methyl-CpG binding protein, MeCP2, and its associated transcription co-repressors such as histone deacetylase 1 and mSin3A to BP4 to repress Bdnf exon IV expression (Martinowich et al., 2003) . In contrast, under depolarizing conditions, DNA methylation at BP4 was reduced accompanied by dissociation of the repression complex and binding of the transcription activator, CREB, to increase Bdnf exon IV expression (Martinowich et al., 2003) .
Similar to this study, negative stressors can also alter Bdnf expression through alterations of DNA methylation pattern at the Bdnf locus resulting in changes in behavior. For example, offspring from dams that experienced variable stress had increased methylation at BP4 in their hippocampus and amygdala when measured at postnatal day 21. This methylation level persisted even up to postnatal day 80 (Boersma et al., 2014) . Correspondingly, Bdnf expression was decreased in these two brain regions at both time points (Boersma et al., 2014) . In a separate study, adult offspring from dams who experienced predator odor stress also had elevated methylation levels at BP4, which reduced Bdnf expression (St-Cyr & Mcgowan, 2015) .
These offspring and those from dams that experienced variable stress when pregnant displayed elevated levels of anxiety and depressionlike behavior (Lee, Brady, Shapiro, Dorsa, & Koenig, 2007; St-Cyr & Mcgowan, 2015) . Although these studies suggest that prenatal stress can elevate DNA methylation at the Bdnf locus, previous studies have shown that negative stressors can reduce maternal caregiving to offspring (Nephew & Bridges, 2011; St-Cyr & Mcgowan, 2015) . In turn, reduced maternal caregiving can mediate undesirable changes to DNA methylation patterns (Weaver et al., 2004) . Given these observations, it is unclear whether DNA methylation changes at the Bdnf locus are due to in utero processes occurring when pregnant dams are stressed, or due to reduced maternal caregiving as a behavioral result of negative stressors. This issue was addressed by a cross fostering study.
In a study where neonatal rats were exposed to abusive maternal care, DNA methylation at BP4 and BP6 was increased in the prefrontal cortex, a change that persisted from infancy into adulthood. This resulted in reduced Bdnf expression in the prefrontal cortex (Roth, Lubin, Funk, & Sweatt, 2009 ). Dams with a history of maltreatment also displayed more anxiety-related behavior and were also abusive to their offspring (Roth et al., 2009) . If neonatal environment plays a bigger role in shaping DNA methylation patterns compared to the prenatal environment, cross fostering should completely reverse elevated levels of DNA methylation at the Bdnf promoters. However, cross fostering to normal caregivers did not reduce DNA methylation at the Bdnf locus back to control levels for offspring from dams with a history of maltreatment (Roth et al., 2009) . Their methylation levels remained significantly higher than those in control offspring (Roth et al., 2009 ).
This, therefore, suggests that methylation changes at the Bdnf locus may occur in utero as a result of negative stress exposure, which can be further enhanced by deficits in maternal care. This study further highlights the possibility of transgenerational inheritance of DNA methylation pattern at the Bdnf locus. Although the mechanism is still not understood, transgenerational effects of negative stressors have been observed in other studies and are reviewed elsewhere (Boersma & Tamashiro, 2015) .
In addition to prenatal and neonatal stress, chronic stress in adult rodents can also cause DNA methylation changes at the BDNF locus in the brain. For example, rats exposed to chronic daily social instability, consisting of unstable housing conditions and non-contact exposure to Methylation of certain histone amino acid residues such as histone 3 Lysine 9 and histone 3 Lysine 27 promote a compact chromatin structure to prevent access of transcription machinery to regulatory regions to mediate transcription. DNA methylation also inhibits transcription factors from binding to their associated binding site at the regulatory regions resulting in transcriptional repression.
a cat while being immobilized in an enclosure, resulted in increased DNA methylation of Bdnf exon IV region at the CA1 region of the hippocampus. This resulted in a corresponding decrease in Bdnf exon IV expression (Roth, Zoladz, Sweatt, & Diamond, 2011) . Other studies using different stress paradigms such as chronic social defeat stress in adult rodents, however, have not observed this finding despite observing changes to Bdnf expression (Roth et al., 2011; Tsankova et al., 2006) . This suggests that negative stressors do not solely operate through DNA methylation, but can also affect Bdnf expression through other epigenetic mechanisms.
Pharmacological agents have been used to determine if DNA methylation patterns mediated by stress can be reversed. Daily administration of the DNA methylation inhibitor zebularine to adult offspring that experienced abusive maternal care successfully reduced DNA methylation level at BP4, resulting in increased Bdnf exon IV expression (Roth et al., 2009) . The use of the mood stabilizer lithium or the antidepressant paroxetine, which is a serotonin reuptake inhibitor, similarly reduced DNA methylation at the Bdnf locus, resulting in increased Bdnf exon IV expression (Dwivedi & Zhang, 2014; Gassen et al., 2015) . This observation is consistent with other studies that have also reported antidepressants reversing methylation patterns induced by stress in other genes (Le Francois et al., 2015; Melas et al., 2012) .
Taken together, these studies highlight that DNA methylation at the Bdnf locus in the brain is malleable to change by negative stressors at different time points during the life of the organism. Importantly, these stress-induced DNA methylation patterns can be reversed by pharmacological agents, such as DNA methylation inhibitors and antidepressants. Although negative stressors can affect Bdnf expression through changes to DNA methylation patterns, they can also affect this change through histone modification. Histone acetylation is the transfer of an acetyl group by histone acetyl-transferases to amino acid residues on the N-terminal tails of histones. This reduces the net positive charge of histones causing histones to reduce their interaction with negatively charged DNA, which, in turn, increases accessibility of transcription factors to DNA to mediate transcription (Nightingale, Wellinger, Sogo, & Becker, 1998; Shogren-Knaak et al., 2006; Tse, Sera, Wolffe, & Hansen, 1998) .
| NEGATIVE STRESS ALTERS BDNF EXPRESSION THROUGH HISTONE MODIFICATION
Presently, acetylation of histone 3 lysine residue 27 (H3K27ac) and lysine residue 9 (H3K9ac) are well described hallmarks of transcription activation as genes containing these histone modifications show upregulation of gene expression (Karmodiya, Krebs, Oulad-Abdelghani, Kimura, & Tora, 2012; Kundaje et al., 2015) .
Histone acetylation is a reversible process and can be removed by histone deacetylases (HDAC) to reduce gene expression (Li, Wu, et al., 2016) . Besides histone acetylation, gene expression can also be regulated by histone methylation.
Histone methylation is the transfer of methyl groups by histone methyltransferases to lysine and arginine residues on the N-terminal tails of histones. Similar to histone acetylation, methylation of certain histone lysine residues such as H3K4 can promote transcription by recruiting transcription factors that mediate chromatin remodeling to facilitate transcription. For example, histone 3 lysine residue 4 (H3K4)
has been associated with an open chromatin structure as it is enriched in transcriptionally active regions (Litt, Simpson, Gaszner, Allis, & Felsenfeld, 2001; Noma, Allis, & Grewal, 2001 ). It facilitates transcription by recruiting members of the histone acetyl-transferases complex for H3 acetylation (Pray-Grant, Daniel, Schieltz, Yates, & Grant, 2005) . Loss of H3K4 methylation reduces transcription (Boa, Coert, & Patterton, 2003; Lefevre, Patel, Kim, Tessarollo, & Dressler, 2010) . In contrast to the methylation of H3K4, methylation of other histone amino acid residues, such as H3K27 and H3K9, promotes a compact chromatin structure resulting in transcriptional repression (Kundaje et al., 2015) . Histone methylation is a reversible process and is mediated by histone demethylases. Together, changes between histone acetylation and methylation enable the expression of genes to be dynamically regulated. This process can be mediated by negative stress.
Exposure to negative stressors at different time points of an organism's life has been shown to alter histone modification patterns that change Bdnf expression. For example, offspring of pregnant mice exposed to restraint stress exhibited anxiety and depression-like behavior (Zheng, Fan, Zhang, & Dong, 2016) . This corresponded with reduced expression of Bdnf exons I, IV, VI, and IX in the hippocampus (Zheng et al., 2016) . The reduction in Bdnf expression was due to elevated HDAC expression, which reduced H3K14 acetylation at these exons (Zheng et al., 2016) . In addition to prenatal stress, exposure to negative stressors during early life can also affect histone modification patterns. Early life stressors such as maternal deprivation resulted in rodents that displayed anxiety and depression-like behavior with memory deficits (Albuquerque Filho et al., 2017; Seo et al., 2016) .
These rodents had increased HDAC expression which reduced total H3 acetylation in the hippocampus, or acetylation of H3 and histone 4
(H4) at BP4, resulting in reduced Bdnf exon IV expression (Albuquerque Filho et al., 2017; Seo et al., 2016) . Similarly, in other studies, female mice exposed to maternal maltreatment also had reduced H3K9/14 acetylation at BDNF promoter IV in their prefrontal cortex. Cross fostering, however, prevented this reduction (Blaze, Asok, & Roth, 2015) . The effect of negative stressors on histone HING ET AL.
| 157 modification patterns is not limited to prenatal and early life, but extends to adulthood.
Exposure to negative stressors during adulthood has been shown to affect histone modification pattern at the Bdnf locus. Adult mice that were exposed to chronic social defeat stress had elevated hippocampal H3K27 methylation at Bdnf promoter III and IV, which are now described as Bdnf promoter IV and VI. This resulted in reduced expression of Bdnf transcripts containing these exons. (Tsankova et al., 2006) . Interestingly, early life stress can exacerbate the effect of negative stress exposure during adulthood, further suppressing Bdnf expression through histone modification. Rats exposed to maternal separation followed by restraint stress when they reach adulthood had much higher HDAC expression in the hippocampus compared to control adult rats that only experienced restraint stress (Seo et al., 2016) . This resulted in greater reduction in H3 and H4 acetylation at
Bdnf promoter IV, which further repressed Bdnf exon IV expression (Seo et al., 2016) . Consistent with the reduction of Bdnf expression, these offspring displayed longer immobility times in the forced swim test compared to control offspring (Seo et al., 2016) .
Although negative stressors can induce changes to histone modification patterns, little is known about whether these patterns can be transmitted across generations. In a recent study, male mice trained to self-administer cocaine had elevated H3 acetylation at Bdnf promoter IV in their sperm (Vassoler, White, Schmidt, Sadri-Vakili, & Pierce, 2013) . Interestingly, these mice sired male offspring that had increased H3 acetylation at Bdnf promoter IV in their medial prefrontal cortex, corresponding with increased expression of Bdnf exon IV transcripts (Vassoler et al., 2013) . This study, therefore, suggests that transmission of histone modification patterns to the next generation is possible at the Bdnf locus. The mechanism for this process is presently unknown. It is also unknown whether this finding can be similarly observed in a stress paradigm. Together, the studies highlight that negative stressors can induce changes to histone modification patterns at any developmental time point to affect Bdnf expression. This change can, however, be reversed by the use of antidepressants.
Antidepressants can reverse transcriptionally repressive histone modification patterns to elevate Bdnf expression. For instance, whereas adult mice with prior exposure to maternal stress had reduced H3 and H4 acetylation at Bdnf promoter IV, escitalopram treatment reduced HDAC expression, increasing acetylation of these histones (Seo et al., 2016) . This increased Bdnf exon IV expression, which reduced immobility time in forced swim test (Seo et al., 2016) .
Antidepressant treatment can also modify patterns of histone modifications in other paradigms to elevate Bdnf expression. In a previous study, imipramine treatment did not reduce the increase of H3K27 methylation at Bdnf promoter IV and VI mediated by chronic social defeat stress (Tsankova et al., 2006) . Instead, H3 and H4 acetylation was elevated due to reduced HDAC5 expression (Tsankova et al., 2006) . This overcame the repressive effect of H3K27 methylation and increased Bdnf exon IV and VI expression, leading to alleviation of anxiety-like behavior (Tsankova et al., 2006) .
In a separate study, mice prenatally exposed to methylmercury showed elevated H3K27 methylation and decreased H3 acetylation, which suppressed Bdnf expression in the dentate gyrus. (Onishchenko, Karpova, Sabri, Castren, & Ceccatelli, 2008 (Onishchenko et al., 2008) . Other medications such as the mood stabilizer valproic acid also directly inhibited HDAC activity, resulting in elevated expression of Bdnf exon IV transcripts in primary neuronal cultures (Yasuda, Liang, Marinova, Yahyavi, & Chuang, 2009 
| DNA METHYLATION PATTERNS AT THE BDNF LOCUS FOR MOOD DISORDER PATIENTS
There are a limited number of studies that have explored DNA methylation pattern at the BDNF locus in mood disorder patients. As it is impractical to explore DNA methylation changes in the brains of patients, studies have relied on exploring disease-associated methylation changes in peripheral tissues as an indirect measure of DNA methylation change in the brain. Supporting this line of approach, genome-wide DNA methylation studies have reported a substantial degree of correlation in DNA methylation patterns between peripheral tissues and the brain (Hing et al., 2015; Smith et al., 2015) . Similarly, a recent study also observed a good correlation in DNA methylation patterns between the brain and peripheral tissues at BP1 and BP4 (Stenz et al., 2015) .
To date, most studies have focused their attention on DNA methylation changes at BP1. In one such study, no methylation difference was observed between peripheral blood of MDD (N = 60) and healthy controls (N = 53) in the CpG island of BP1 (Choi et al., 2015) . A more recent study, however, identifed two CpGs in the CpG island that had increased methylation in MDD patients (N = 65) compared to healthy controls (N = 65) (Na et al., 2016) . This study, however, did not control for the effect of medications as participants with MDD were on mood stabilizers and antidepressants. Another study that observed methylation changes at BP1 in MDD patients also did not control for antidepressant use (Fuchikami et al., 2011) . It is uncertain whether these methylation changes are due to MDD or the use of antidepressants.
In contrast to the studies mentioned, an investigation that excluded participants on mood stabilizers and antipsychotics observed that peripheral blood mononuclear cells (PBMCs) of MDD patients (N = 24) had higher methylation in BP1 compared to healthy controls (N = 20) (Roy, Shelton, & Dwivedi, 2017) . This elevation was driven by MDD patients who experienced suicidal ideation (N = 14), as stratification of MDD patients into suicidal ideation and non-suicidal ideation groups showed that those with ideation had higher methylation than controls (Roy et al., 2017) . In comparison, no significant difference in DNA methylation at BP1 was observed between MDD patients without suicidal ideation (N = 10) and healthy controls (Roy et al., 2017) . Consistent with the absence of methylation change in MDD, a separate study also observed no difference in methylation at BP1 in the PBMC of MDD without antidepressant medication (N = 25) and healthy controls (N = 278) (Carlberg et al., 2014) . A larger study which controlled for medication also showed no methylation differences between elderly individuals with depression (N = 251) compared to non-depressed controls in BP1 (N = 773) (Januar, Ancelin, Ritchie, Saffery, & Ryan, 2015) . However, this study used buccal cells instead of blood. Buccal cells and blood are distinctly different tissues with different DNA methylation patterns (Smith et al., 2015) . Another study which assessed methylation pattern in the saliva 
| CONCLUSIONS AND FUTURE DIRECTIONS
In this review, we have highlighted empirical support for the involvement of BDNF in mood disorders that is consistent between animal studies and clinical studies. Indeed, reduced periperal BDNF levels have been observed in MDD patients, which ties in with its reduction in gene expression in the brains of stressed rodents that exhbit anxiety and depression-like behavior. In contrast, there is presently a lack of agreement between animal studies and clinical studies on the mechanism that mediates this gene expression change in mood disorder, with mixed results in both genetic and epigenetic studies. Although knock-in mice that contain the methionine allele of rs6265 demonstrate heightened sensitivity to negative stressors and increased display of depression-like behavior (Yu et al., 2012) , there is inconclusive evidence to support the association of rs6265 with MDD.
Similarly, whereas animal studies have reported increased DNA methylation and altered histone methylation and acetylation in the brains of stressed rodents that display depression-like behavior, no conclusive change in DNA methylation has been observed in the peripheral tissues of mood disorder patients. In addition, there are presently no reports exploring histone modification changes in peripheral tissues of mood disorder patients. These discrepancies between animal and clinical studies are in part due to the inherent challenges involved in conducting clinical studies. These challeneges include small sample sizes, which limit statistical power to detect differences, heterogeneity in psychiatric phenotypes, differences in tissue samples used, and medication use, which can influence the outcome and interpretation of the results.
A motivation for identifying changes to BDNF expression or epigenetic changes at its locus is to use these as biomarkers for MDD.
The observation that peripheral BDNF levels vary with mood disorders makes this possibility a promising one. However, there is a large degree of variation in peripheral BDNF protein levels across mood disorders, which reduces the likelihood that this measure can be translated into a useful biomarker for MDD in clinical practice (Fernandes et al., 2014) .
Similarly for DNA methylation, present studies have not found While peripheral BDNF levels may not be a useful biomarker to distinguish between mood disorders, a potential alternative solution is the use of mature BDNF/pro-BDNF ratio for discrimination. As mentioned, pro-BDNF broadly functions to oppose neuroplasticity processes mediated by mature BDNF. Exposure of rodents to negative stressors increases pro-BDNF expression in the brain resulting in cellular processes such as reduction in arborization, impaired LTP, and enhanced LTD. These processes can impair cognition and promote depression-like behavior (Bai et al., 2016) . Due to limited specificity of previous anti-BDNF antibodies, previous studies of human peripheral BDNF levels did not discriminate between mature BDNF and pro-BDNF. However, a study using an enzyme-linked immunosorbent assay that could distinguish between mature BDNF and pro-BDNF showed that both forms are highly expressed in human serum (Yoshida, Ishikawa, Iyo, & Hashimoto, 2012) . Pro-BDNF is however ∼3-fold lower in expression than mature BDNF (Yoshida, Ishikawa, Iyo, et al., 2012) . Using this approach, medicated MDD patients (N = 69)
were observed to have no difference in serum levels of pro-BDNF, while levels of mature BDNF were decreased relative to healthy controls (N = 78) (Yoshida, Ishikawa, Niitsu, et al., 2012) . In contrast, medicated bipolar disorder patients had lower pro-BDNF serum levels, while elevated mature BDNF serum level compared to controls (Sodersten et al., 2014) .
Given the difference in expression between mature BDNF and pro-BDNF in mood disorder patients, multivariate logistic analysis successfully discriminated between BD and healthy controls using the mature BDNF/pro-BDNF ratio as a significant predictor in two independent cohorts, the Shlgrenska (N = 47:43; case:control) and Karolinska (N = 215:112; case:control) cohorts (Sodersten et al., 2014) .
Using this model, the sensitivity for the Sahlgrenska cohort was 89%, while it was 74% in the Karolinska cohort. The specificity was 77% and 64%, respectively, (Sodersten et al., 2014) . A more recent study also demonstrated that the mature BDNF/pro-BDNF ratio could discriminate between MDD (N = 37) and BD (N = 24) patients. It distinguished between BD depression from MDD with a sensitivity of ∼84% and specificity of 83% (Zhao et al., 2017) . This suggests that the mature BDNF/pro-BDNF ratio may be a useful biomarker for mood disorders.
Further studies are required to validate these findings. In addition to using the mature BDNF/pro-BDNF ratio, other directions are also available for discoverying epigenetic biomarkers of mood disorders.
A limitation to the present approach in identifying diseaseassociated DNA methylation sites at the BDNF locus is its focus on BDNF promoter regions. Despite its importance in regulating gene expression, transcription regulatory regions outside of promoters, such as enhancers, also play an important role in maintaining appropriate levels of gene expression. Indeed, methylation changes at these regions have been shown to alter gene expression contributing to disease. One such example is the methylation change observed at an enhancer in intron 7 of the FK506-Binding Protein-5 (FKBP5) gene in post traumatic stress syndrome (PTSD) patients (Klengel et al., 2013) . Given this, identification of DNA methylation variation in enhancers surrounding the BDNF gene for would provide further opportunities to identify disease-associated changes in mood disorders.
Although much focus has been on studying DNA methylation in cytosines of CpG dinucleotides, methylation of cytosines in non-CpG contexts might also contribute to mood disorders. Previous studies have provided correlative evidence suggesting that non-CpG methylation may regulate gene expression. For example, non-CpG methylation at promoters of imprinted genes negatively correlates with gene expression in mouse prefrontal cortex (Xie et al., 2012) .
Similarly, another study showed that expressed genes with genic nonCpG methylation in mouse and human brains increased their transcript abundance when non-CpG methylation was depleted (Lister et al., 2013) . In line with these studies, direct molecular evidence was provided to show that non-CpG methylation regulates gene expression. HEK-293 cells transfected with reporter gene plasmids containing non-CpG methylation were less likely to express the reporter gene (Guo et al., 2014) . Furthermore, reducing non-CpG methylation but leaving CpG methylation unchanged at particular loci increased mRNA expression of those non-CpG methylated genes (Guo et al., 2014) .
Importantly, non-CpG methylation in adult mouse neurons was observed to be conserved in the adult human brain (Guo et al., 2014) . Given this work, future studies focusing on non-CpG methylation at the BDNF locus could shed light on its involvement in mood disorders.
5-hydroxymethylcytosine (5hmC) is another mark that affects behavior. It is thought to be an intermediate metabolic product of oxidized methylated cytosine and is able to alleviate transcriptional repression mediated by 5-methylcytosines (Branco, Ficz, & Reik, 2011) . 5-Hydroxymethylcytosine regulates mammalian brain development and physiological mechanisms such as neurogenesis (Hahn et al., 2013; Lister et al., 2013) . In a recent study, negative stressors were shown to alter 5hmC levels. Mice exposed to prenatal stress had elevated 5hmC levels at the Bdnf locus in the frontal cortex and hippocampus, resulting in altered Bdnf expression (Dong et al., 2015) . Future studies should explore 5hmC patterns in MDD to determine if this mark is indeed altered at the BDNF locus in patients.
In conclusion, appropriate BDNF expression plays an important role in regulating behavior. Although BDNF expression is altered in animals exposed to negative stressors as they are in MDD patients, there is presently a lack of agreement between human and animal studies regarding the genetic and epigenetic contributors to these psychiatric disorders. Further studies with better controls are required to validate current findings. Furthermore, other avenues also exist in epigenetics, such as histone modification, 5-hydroxymethylcytosine and non-CpG methylation, that may be explored in MDD. It is hoped that by studying these processes, investigators will have a better understanding as to the pathophysiologic mechanisms involved in MDD and identify other genes that may be involved in this disorder. In the process, novel biomarkers could be discovered to aid in the diagnosis and treatment of MDD.
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